HLA-DP多态性与中国南北汉族人群HBV相关性肝病遗传易感性的研究
|
摘要
[研究目的]HLA-DP(Human leukocyte antigen DP)多态性已经在日本和泰国人群中证明与HBV(hepatitis B virus)感染有关。我们的目的是检验这种关联性是否能在中国汉族人群中重复。
[研究方法]采用Tap-man MGB探针法,将HLA-DPA1 rs2395309和HLA-DPB1 rs9277535 (HLA-DP基因座上最强关联的两SNPs)在三个独立的汉族人群中分型,包括2805例乙肝感染者和1796例对照。通过SPSS17.0软件对分型结果进行关联分析。通过Arlequin 3.5和haploview 4.2软件分析人群的异质性及单体型。
[实验结果]通过logistic回归分析,两SNPs与南北汉族HBV的感染和感染后清除均呈显著相关(rs2395309 P=0.021-3.36×10-8；rs9277535 P=8.37×10-3-2.68×10-10)。此外,HLA-DPA1 rs2395309和HLA-DPB1 rs9277535的基因型分布在中国南北汉族人群中存在着很大差异。通过使用HBV无症状携带者作为对照,我们的实验发现HLA-DP两SNPs的变异与HBV感染后恶性化转归并无关联性(南方人群rs2395309P=0.305-0.822,rs9277535 P=0.163-0.881；北方人群rs2395309 P=0.097-0.697,rs9277535 P=0.198-0.615)
[实验结论]HLA-DP基因座上的两SNPs (rs2395309, rs9277535)在中国南北汉族人群中与HBV的感染和感染后清除均呈显著相关,但不与HBV恶性化转归有关。简而言之,携带HLA-DP保护等位基因的人群不易感染HBV,感染后也易清除。
[研究目的]为了更有力的支持第一部分的结论,检索最新的HLA-DP研究成果,我们对HLA-DP多态性与HBV相关性肝病的研究文献进行了一个Meta分析。
[研究方法]采用系统查询的方法检索PubMe、google学术、Scirus、中国知网、万方等国内外数据库。设定文献纳入和排除标准,将提取到的数据输入统计学软件Stata中,进行同质性检验、构建固定效应模型／随机效应模型、检测出版偏倚等Meta分析步骤。
[实验结果]对所检索到的23篇文献按纳入和剔除标准进行筛选,最终得到10篇可用于汇总的文献。根据不同的疾病表现对本Meta分析分为三类：1.HLA-DP与HBV清除的Meta分析。其结果取得了最好的荟萃效应,rs9277535、rs2395309两位点合并后均不存在异质性(P>0.05)；2.HLA-DP与HBV肝癌Meta的分析。结果与第一部分一样,均是阴性,但荟萃文献中有不同观念；3. HLA-DP与HBV感染的Meta分析。其结果中存在很大的异质性,rs9277535固定效应模型时12=69.8%,P=0.002,随机效应模型时12=63.9%,P=0.007。
[实验结论]通过Meta分析,我们进一步确认HLA-DP rs9277535、rs2395309与HBV感染和感染后清除有着密切关系,而HLA-DP上的某些位点可能是HBV肝癌的易感SNPs,但其确切关系需要更大规模研究的证实。
Background and purpose:Human leukocyte antigen DP(HLA-DP) locus has been reported to be associated with hepatitis B virus (HBV) infection in populations of Japan and Thailand. We aimed to examine whether the association can be replicated in Han Chinese.
Methods:By using Tap-man MGB probe, two HLA-DP variants rs2395309 and rs9277535 (the most strongly associated SNPs from each HLA-DP locus) were genotyped in three independent Han cohorts consisting of 2805 cases and 1796 controls. The SPSS 17.0 Software was analyzed for the genotyped results. By using Arlequin 3.5 and haploview 4.2 software, we got the informations of population heterogeneity and haplotypes.
Results:By using logistic regression analysis, these two SNPs in the HLA-DPA1 and HLA-DPB1 genes were significantly associated with HBV infection in Han Chinese populations (P=0.021-3.36×10-8at rs2395309; P=8.37×10-3-2.68×l0-10at rs9277535). In addition, the genotype distributions of both sites (rs2395309 and rs9277535) were clearly different between southern and northern Chinese population (P=8.95×10-5 at rs2395309; P =1.64×10-9 at rs9277535). By using asymptomatic HBV carrier as control group, our study showed that there were no associations of two HLA-DP variants with HBV progression (P =0.305～0.822 and 0.163～0.881 in southern Chinese population, respectively; P= 0.097～0.697 and 0.198～0.615 in northern Chinese population, respectively).
Conclusion:Our results confirmed that two SNPs (rs2395309 and rs9277535) in the HLA-DP loci were strongly associated with HBV infection in southern and northern Han Chinese populations, but not with HBV progression.In a word, HLA-DP polymorphisms only participated in HBV infection, but did not participate in the carcinogenesis of HBV.
Background and purpose:In order to support for the conclusion of the first part and get the latest paper, we performed a Meta-analysis for the HLA-DP polymorphism with HBV-related liver disease.
Methods:After setting criteria, we retrieval the related papers by using Pubmed, google academic, Scirus and other literature database. The data, which is extracted from papers, were put into the Stata statistical software. Meta-analysis include Homogeneity test, building a fixed effects model/random effects model, detecting publication bias and other steps.
Results:According to the screening criteria, we choose 10 papers from the initial 23. On the base of the different disease, the Meta-analysis were divided into three categories. First, the Meta-analysis of the relationship between HLA-DP and HBV clearance achieved the best results, and the two SNPs meet heterogeneity (P＞0.05). Second, the results of HLA-DP and HBV-related liver cancer were negative, like the conclusion of the first part. Third, there was great heterogeneous in the Meta-analysis of HLA-DP and HBV infection. In rs9277535, the heterogeneity is I2=69.8%, P=0.002 in fixed effect model, and I2=63.9%, P=0.007 in random effects model.
Conclusion:By Meta-analysis, we further confirmed that the strong associations between HLA-DP rs9277535, rs2395309 and HBV infections/Clear. Besides, some sites in the HLA-DP may be susceptible to HBV-related liver cancer, but the relationships require more study.
[研究方法]采用Tap-man MGB探针法,将HLA-DPA1 rs2395309和HLA-DPB1 rs9277535 (HLA-DP基因座上最强关联的两SNPs)在三个独立的汉族人群中分型,包括2805例乙肝感染者和1796例对照。通过SPSS17.0软件对分型结果进行关联分析。通过Arlequin 3.5和haploview 4.2软件分析人群的异质性及单体型。
[实验结果]通过logistic回归分析,两SNPs与南北汉族HBV的感染和感染后清除均呈显著相关(rs2395309 P=0.021-3.36×10-8；rs9277535 P=8.37×10-3-2.68×10-10)。此外,HLA-DPA1 rs2395309和HLA-DPB1 rs9277535的基因型分布在中国南北汉族人群中存在着很大差异。通过使用HBV无症状携带者作为对照,我们的实验发现HLA-DP两SNPs的变异与HBV感染后恶性化转归并无关联性(南方人群rs2395309P=0.305-0.822,rs9277535 P=0.163-0.881；北方人群rs2395309 P=0.097-0.697,rs9277535 P=0.198-0.615)
[实验结论]HLA-DP基因座上的两SNPs (rs2395309, rs9277535)在中国南北汉族人群中与HBV的感染和感染后清除均呈显著相关,但不与HBV恶性化转归有关。简而言之,携带HLA-DP保护等位基因的人群不易感染HBV,感染后也易清除。
[研究目的]为了更有力的支持第一部分的结论,检索最新的HLA-DP研究成果,我们对HLA-DP多态性与HBV相关性肝病的研究文献进行了一个Meta分析。
[研究方法]采用系统查询的方法检索PubMe、google学术、Scirus、中国知网、万方等国内外数据库。设定文献纳入和排除标准,将提取到的数据输入统计学软件Stata中,进行同质性检验、构建固定效应模型／随机效应模型、检测出版偏倚等Meta分析步骤。
[实验结果]对所检索到的23篇文献按纳入和剔除标准进行筛选,最终得到10篇可用于汇总的文献。根据不同的疾病表现对本Meta分析分为三类：1.HLA-DP与HBV清除的Meta分析。其结果取得了最好的荟萃效应,rs9277535、rs2395309两位点合并后均不存在异质性(P>0.05)；2.HLA-DP与HBV肝癌Meta的分析。结果与第一部分一样,均是阴性,但荟萃文献中有不同观念；3. HLA-DP与HBV感染的Meta分析。其结果中存在很大的异质性,rs9277535固定效应模型时12=69.8%,P=0.002,随机效应模型时12=63.9%,P=0.007。
[实验结论]通过Meta分析,我们进一步确认HLA-DP rs9277535、rs2395309与HBV感染和感染后清除有着密切关系,而HLA-DP上的某些位点可能是HBV肝癌的易感SNPs,但其确切关系需要更大规模研究的证实。
Background and purpose:Human leukocyte antigen DP(HLA-DP) locus has been reported to be associated with hepatitis B virus (HBV) infection in populations of Japan and Thailand. We aimed to examine whether the association can be replicated in Han Chinese.
Methods:By using Tap-man MGB probe, two HLA-DP variants rs2395309 and rs9277535 (the most strongly associated SNPs from each HLA-DP locus) were genotyped in three independent Han cohorts consisting of 2805 cases and 1796 controls. The SPSS 17.0 Software was analyzed for the genotyped results. By using Arlequin 3.5 and haploview 4.2 software, we got the informations of population heterogeneity and haplotypes.
Results:By using logistic regression analysis, these two SNPs in the HLA-DPA1 and HLA-DPB1 genes were significantly associated with HBV infection in Han Chinese populations (P=0.021-3.36×10-8at rs2395309; P=8.37×10-3-2.68×l0-10at rs9277535). In addition, the genotype distributions of both sites (rs2395309 and rs9277535) were clearly different between southern and northern Chinese population (P=8.95×10-5 at rs2395309; P =1.64×10-9 at rs9277535). By using asymptomatic HBV carrier as control group, our study showed that there were no associations of two HLA-DP variants with HBV progression (P =0.305～0.822 and 0.163～0.881 in southern Chinese population, respectively; P= 0.097～0.697 and 0.198～0.615 in northern Chinese population, respectively).
Conclusion:Our results confirmed that two SNPs (rs2395309 and rs9277535) in the HLA-DP loci were strongly associated with HBV infection in southern and northern Han Chinese populations, but not with HBV progression.In a word, HLA-DP polymorphisms only participated in HBV infection, but did not participate in the carcinogenesis of HBV.
Background and purpose:In order to support for the conclusion of the first part and get the latest paper, we performed a Meta-analysis for the HLA-DP polymorphism with HBV-related liver disease.
Methods:After setting criteria, we retrieval the related papers by using Pubmed, google academic, Scirus and other literature database. The data, which is extracted from papers, were put into the Stata statistical software. Meta-analysis include Homogeneity test, building a fixed effects model/random effects model, detecting publication bias and other steps.
Results:According to the screening criteria, we choose 10 papers from the initial 23. On the base of the different disease, the Meta-analysis were divided into three categories. First, the Meta-analysis of the relationship between HLA-DP and HBV clearance achieved the best results, and the two SNPs meet heterogeneity (P＞0.05). Second, the results of HLA-DP and HBV-related liver cancer were negative, like the conclusion of the first part. Third, there was great heterogeneous in the Meta-analysis of HLA-DP and HBV infection. In rs9277535, the heterogeneity is I2=69.8%, P=0.002 in fixed effect model, and I2=63.9%, P=0.007 in random effects model.
Conclusion:By Meta-analysis, we further confirmed that the strong associations between HLA-DP rs9277535, rs2395309 and HBV infections/Clear. Besides, some sites in the HLA-DP may be susceptible to HBV-related liver cancer, but the relationships require more study.
引文
[1]LU F, ZHUANG H. Management of hepatitis B in China [J]. Chin Med J (Engl),2009.
[2]World Health Organization. Hepatitis B. World Health Organization Fact Sheet No. 204. Available at:http://who.int/mediacentre/factsheets/fs204/en (Revised August 2008).
[3]KAMATANI Y, WATTANAPOKAYAKIT S, OCHI H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians [J]. Nature genetics,2009,41(5):591-595.
[4]AN P, WINKLER C, GUAN L, et al. A Common HLA-DPA1 Variant is a Major Determinant of Hepatitis B Virus Clearance in Han Chinese [J]. Journal of Infectious Diseases,2011,203(7):943.
[5]GUO X, ZHANG Y, LI J, et al. Strong Influence of HLA-DP Gene Variants on Development of Persistent Chronic HBV Carriers in the Han Chinese Population [J]. Hepatology (Baltimore, Md),2011,53(2):422.
[6]HU L, ZHAI X, LIU J, et al. Genetic variants in HLA-DP/DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development [J]. Hepatology,2011,
[7]LI J, YANG D, HE Y, et al. Associations of HLA-DP Variants with Hepatitis B Virus Infection in Southern and Northern Han Chinese Populations:A Multicenter Case-Control Study [J]. PloS one,2011,6(8):e24221.
[8]MBAREK H, OCHI H, URABE Y, et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population [J]. Human molecular genetics,2011,20(19):3884-3892.
[9]O'BRIEN T, KOHAAR I, PFEIFFER R, et al. Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver [J]. Genes and immunity,2011,12(6):428-433.
[10]PNG E, THALAMUTHU A, ONG R T H, et al. A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region [J]. Human molecular genetics,2011,20(19):3893-3898.
[11]VERMEHREN J, L TSCH J, SUSSER S, et al. A Common HLA-DPA1 Variant Is Associated with Hepatitis B Virus Infection but Fails to Distinguish Active from Inactive Caucasian Carriers [J]. PloS one,2012,7(3):e32605.
[12]WANG L, WU X P, ZHANG W, et al. Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese:two independent case-control studies [J]. PloS one,2011.
[1]World Health Organization. Hepatitis B. World Health Organization Fact Sheet No. 204. Available at:http://who.int/mediacentre/factsheets/fs204/en (Revised August 2008).
[2]LU F, ZHUANG H. Management of hepatitis B in China [J]. Chin Med J (Engl),2009, 122(1):3-4.
[3]EUROPEAN ASSOCIATION FOR THE STUDY OF THE L. EASL Clinical Practice Guidelines:Management of chronic hepatitis B virus infection [J]. J Hepatol,2012.
[4]BAUMERT T F, THIMME R, VON WEIZSACKER F. Pathogenesis of hepatitis B virus infection [J]. World Journal of Gastroenterology,2007,13(1):82.
[5]CHISARI F V, ISOGAWA M, WIELAND S F. Pathogenesis of hepatitis B virus infection [J]. Pathologie Biologie,2010,58(4):258-266.
[6]BERTOLETTI A, FERRARI C. Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection [J]. Gut,2011.
[7]BAUER T, SPRINZL M, PROTZER U. Immune control of hepatitis B virus [J]. Digestive Diseases,2011,29(4):423-433.
[8]DUNN C, PEPPA D, KHANNA P, et al. Temporal Analysis of Early Immune Responses in Patients With Acute Hepatitis B Virus Infection [J]. Gastroenterology,2009, 137(4):1289-1300.
[9]KAMATANI Y, WATTANAPOKAYAKIT S, OCHI H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians [J]. Nature Genetics,2009,41(5):591-595.
[10]ZHANG H, ZHAI Y, HU Z, et al. Genome-wide association study identifies Ip36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers [J]. Nature Genetics,2010,42(9):755-758.
[11]THURSZ M R, KWIATKOWSKI D, ALLSOPP C E, et al. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia [J]. N Engl J Med, 1995,332(16):1065-1069.
[12]JIANG Y G, WANG Y M, LIU T H, et al. Association between HLA class Ⅱ gene and susceptibility or resistance to chronic hepatitis B [J]. World Journal of Gastroenterology, 2003,9(10):2221-2225.
[13]AHN S H, HAN K H, PARK J Y, et al. Association between hepatitis B virus infection and HLA-DR type in Korea [J]. Hepatology,2000,31(6):1371-1373.
[14]卫生部.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6)：324-329.
[15]中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病 与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9)：643-646.
[16]王宇明,张南.从慢加急性肝衰竭(ACLF)共识讨论到肝衰竭定义和分型诊断,F,2009[C].
[17]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病杂志,2011,19(1)：13-24.
[18]WILLIAM M, ANNE M, R.TODD. AASLD position paper:The management of acute liver failure:Update 2011 [J]. Hepatology,2011,8.
[19]DENG G, ZHOU G, ZHANG R, et al. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers [J]. Gastroenterology,2008,134(3):716-726. e712.
[20]DIENSTAG J L. Hepatitis B virus infection [J]. New England Journal of Medicine, 2008,359(14):1486-1500.
[21]GANEM D, PRINCE A M. Hepatitis B virus infection—natural history and clinical consequences [J]. New England Journal of Medicine,2004,350(11):1118-1129.
[22]LOK A S F, MCMAHON B J. Chronic hepatitis B:update 2009 [J]. Hepatology,2009, 50(3):661-662.
[23]SARIN S K, KUMAR A, ALMEIDA J A, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) [J]. Hepatology international,2009,3(1):269-282.
[24]PRIETO J. Inflammation, HCC and sex:IL-6 in the centre of the triangle [J]. Journal of Hepatology,2008,48(2):380-381.
[25]CHEN S, YEH J, CHANG M, et al. Gender Difference of Alanine Aminotransferase Elevation May Be Associated with Higher Hemoglobin Levels among Male Adolescents [J]. PLoS ONE,2010,5(10):e13269.
[26]NAUGLER W, SAKURAI T, KIM S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production [J]. Science,2007,317(5834):121.
[27]WANG S-H, YEH S-H, LIN W-H, et al. Identification of androgen response elements in the enhancer I of hepatitis B virus:A mechanism for sex disparity in chronic hepatitis B [J]. Hepatology,2009,50(5):1392-1402.
[28]TRACHTENBERG E, VINSON M, HAYES E, et al. HLA class Ⅰ (A, B, C) and class Ⅱ (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China [J]. Tissue antigens,2007,70(6):455-463.
[29]YANG G, DENG Y J, HU S N, et al. HLA-A,-B, and -DRB1 polymorphism defined by sequence-based typing of the Han population in Northern China [J]. Tissue antigens, 2006,67(2):146-152.
[30]SINGH R, KAUL R, KAUL A, et al. A comparative review of HLA associations with hepatitis B and C viral infections across global populations [J]. WORLD JOURNAL OF GASTROENTEROLOGY,2007,13(12):1770.
[31]WEN B, LI H, LU D, et al. Genetic evidence supports demic diffusion of Han culture [J]. Nature,2004,431(7006):302-305.
[32]ZHANG F, SU B, ZHANG Y P, et al. Genetic studies of human diversity in East Asia [J]. Philos Trans R Soc Lond B Biol Sci,2007,362(1482):987-995.
[33]ZHAO T M, LEE T D. Gm and Km allotypes in 74 Chinese populations:a hypothesis of the origin of the Chinese nation [J]. Hum Genet,1989,83(2):101-110.
[34]CHAIX R, CAO C, DONNELLY P. Is mate choice in humans MHC-dependent? [J]. PLoS Genet,2008,4(9):e1000184.
[35]BARREIRO L B, QUINTANA-MURCI L. From evolutionary genetics to human immunology:how selection shapes host defence genes [J]. Nat Rev Genet,2010,11(1): 17-30.
[36]PRUGNOLLE F, MANICA A, CHARPENTIER M, et al. Pathogen-driven selection and worldwide HLA class Ⅰ diversity [J]. Curr Biol,2005,15(11):1022-1027.
[37]ZENG G, WANG Z, WEN S, et al. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China [J]. J Viral Hepat,2005,12(6): 609-617.
[38]HUANG Z J, ZHOU M G, WANG L J. Study on the geographic distribution of liver cancer mortality and HBsAg carrier rate in China [J]. Disease Surveillance (Chinese),2007, 22(4):242-245.
[39]GIOVANNA F, BORTOLOTTI F, FRANCESCO D. Natural history of chronic hepatitis B:Special emphasis on disease progression and prognostic factors☆ [J]. Journal of Hepatology,2008,48(2):335-352.
[40]YANG H, LU S, LIAW Y, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma [J]. New England Journal of Medicine,2002,347(3):168.
[41]HANDUNNETTHI L, RAMAGOPALAN S V, EBERS G C, et al. Regulation of major histocompatibility complex class Ⅱ gene expression, genetic variation and disease [J]. Genes and Immunity,2009,11(2):99-112.
[42]LLOVET J M, BURROUGHS A, BRUIX J. Hepatocellular carcinoma [J]. Lancet, 2003,362(9399):1907-1917.
[43]CHEN J D, YANG H I, ILOEJE U H, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death [J]. Gastroenterology,2010, 138(5):1747-1754. e1741.
[44]ZHOU Y H, WU C, ZHUANG H. Vaccination against hepatitis B:the Chinese experience [J]. Chin Med J (Engl),2009,122(1):98-102.
[45]ZHANG H, ZHAI Y, HU Z, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers [J]. Nat Genet,2010,42(9):755-758.
[46]GRIVENNIKOV S I, GRETEN F R, KARIN M. Immunity, Inflammation, and Cancer [J]. Cell,2010,140(6):883-899.
[1]VISSCHER P M, BROWN M A, MCCARTHY M I, et al. Five Years of GWAS Discovery [J]. American journal of human genetics,2012,90(1):7.
[2]GIBSON G. Rare and common variants:twenty arguments [J]. Nature Reviews Genetics,2012,13(2):135-145.
[3]DAVEY, HOHENLOHE, ETTER, et al. Genome-wide genetic marker discovery and genotyping using next-generation sequencing [J]. Nature Reviews Genetics,2011,12(7).
[4]RAYCHAUDHURI S. Mapping rare and common causal alleles for complex human diseases [J]. Cell,2011,147(1):57-69.
[5]PRICE, ZAITLEN, REICH D, et al. New approaches to population stratification in genome-wide association studies [J]. Nature Reviews Genetics,2010,11(7):459-463.
[6]JACOBS K B, YEAGER M, WACHOLDER S, et al. A new statistic and its power to infer membership in a genome-wide association study using genotype frequencies [J]. Nature genetics,2009,41(11):1253-1257.
[7]CANTOR R M, LANGE K, SINSHEIMER J S. Prioritizing GWAS results:A review of statistical methods and recommendations for their application [J]. The American Journal of Human Genetics,2010,86(1):6-22.
[8]DERSIMONIAN R, LAIRD N. Meta-analysis in clinical trials [J]. Controlled clinical trials,1986,7(3):177-188.
[9]HEDGES L V, OLKIN I, STATISTIKER M. Statistical methods for meta-analysis [M]. Academic Press Orlando, FL.1985.
[10]STROUP D F, BERLIN J A, MORTON S C, et al. Meta-analysis of observational studies in epidemiology [J]. JAMA:the journal of the American Medical Association,2000, 283(15):2008-2012.
[11]HIGGINS J, THOMPSON S G Quantifying heterogeneity in a meta-analysis [J]. Statistics in medicine,2002,21(11):1539-1558.
[12]EGGER M, SMITH G D, SCHNEIDER M, et al. Bias in meta-analysis detected by a simple, graphical test [J]. Bmj,1997,315(7109):629-634.
[13]KAMATANI Y, WATTANAPOKAYAKIT S, OCHI H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians [J]. Nature genetics,2009,41(5):591-595.
[14]VERMEHREN J, L TSCH J, SUSSER S, et al. A Common HLA-DPA1 Variant Is Associated with Hepatitis B Virus Infection but Fails to Distinguish Active from Inactive Caucasian Carriers [J]. PloS one,2012,7(3):e32605.
[15]YAN Z, TAN S, DAN Y, et al. Relationship between HLA-DP gene polymorphisms and clearance of chronic hepatitis B virus infections:Case-control study and meta-analysis [J]. Infect Genet Evol,2012,
[16]PNG E, THALAMUTHU A, ONG R T H, et al. A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region [J]. Human molecular genetics,2011,20(19):3893-3898.
[17]THOMAS R, THIO C L, APPS R, et al. A novel variant marking HLA-DP Expression Levels Predicts Hepatitis B Virus Recovery [J]. Journal of Virology,2012,
[18]AN P, WINKLER C, GUAN L, et al. A Common HLA-DPA1 Variant is a Major Determinant of Hepatitis B Virus Clearance in Han Chinese [J]. Journal of Infectious Diseases,2011,203(7):943.
[19]GUO X, ZHANG Y, LI J, et al. Strong Influence of HLA-DP Gene Variants on Development of Persistent Chronic HBV Carriers in the Han Chinese Population [J]. Hepatology (Baltimore, Md),2011,53(2):422.
[20]LI J, YANG D, HE Y, et al. Associations of HLA-DP Variants with Hepatitis B Virus Infection in Southern and Northern Han Chinese Populations:A Multicenter Case-Control Study [J]. PloS one,2011,6(8):e24221.
[21]WANG L, WU X P, ZHANG W, et al. Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese:two independent case-control studies [J]. PloS one,2011, 6(3):e17608.
[22]HU L, ZHAI X, LIU J, et al. Genetic variants in HLA-DP/DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development [J]. Hepatology,2011,
[23]MBAREK H, OCHI H, URABE Y, et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population [J]. Human molecular genetics,2011,20(19):3884-3892.
[24]O'BRIEN T, KOHAAR I, PFEIFFER R, et al. Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver [J]. Genes and immunity,2011,12(6):428-433.
[25]RAYCHAUDHURI S, SANDOR C, STAHL E A, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis [J]. Nature genetics,2012,44(3):291-296.
[26]COZEN W, LI D, BEST T, et al. A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32 [J]. Blood,2012,119(2):469-475.
[27]VIGNAL C M, BANS AL A T, BALDING D J. Using Penalised Logistic Regression to Fine Map HLA Variants for Rheumatoid Arthritis [J]. Annals of Human Genetics,2011,
[28]NOGUCHI E, SAKAMOTO H, HIROTA T, et al. Genome-wide association study identifies HLA-DP as a susceptibility gene for pediatric asthma in asian populations [J]. PLoS genetics,2011,7(7):e1002170.
[29]IVANSSON E, JUKO-PECIREP I, ERLICH H, et al. Pathway-based analysis of genetic susceptibility to cervical cancer in situ:HLA-DPB1 affects risk in Swedish women [J]. Genes and immunity,2011,
[30]ZHOU X, LEE J E, ARNETT F C, et al. HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis:A genome-wide association study in Koreans with replication in North Americans [J]. Arthritis & Rheumatism,2009,60(12):3807-3814.
[31]MOONS AMY P, BONELLA P, GOODWIN G, et al. The identification of a new HLA-DPB1 allele (* 1302) in one family and the detection of a recombination event between the DR and the DQ regions in another Caucasian T1DGC family [J]. Tissue antigens,2009,74(3):268-270.
[32]SELVARAJ P, RAGHAVAN S, SWAMINATHAN S, et al. HLA-DQB1 and -DPB1 allele profile in HIV infected patients with and without pulmonary tuberculosis of south India [J]. Infect Genet Evol,2008,8(5):664-671.
[33]HOLLENBACH J A, MADBOULY A, GRAGERT L, et al. A combined DPA1 approximately DPB1 amino acid epitope is the primary unit of selection on the HLA-DP heterodimer [J]. Immunogenetics,2012,
[34]ANDREATTA M, NIELSEN M. Characterizing the binding motifs of 11 common human HLA-DP and HLA-DQ molecules using NNAlign [J]. Immunology,2012,
[35]LAUTERBACH N, VOORTER C, STALLINGA C, et al. Full-length HLA-DPB1 diversity in multiple alleles of individuals from Caucasian, Black, or Oriental origin [J]. Tissue antigens,2012,
[36]LV N, DANG A, WANG Z, et al. Association of susceptibility to Takayasu arteritis in Chinese Han patients with HLA-DPB1 [J]. Human Immunology,2011,
[37]TRAVIS R C, REEVES G K, GREEN J, et al. Gene-environment interactions in 7610 women with breast cancer:prospective evidence from the Million Women Study [J]. The Lancet,2010,375(9732):2143-2151.
[1]FDA. Pharmacogenomic Biomarkers in Drug. Available at:http://www.fda.gov/Drugs /ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378htm(Updated 04/26/2012).
[2]EASL Clinical Practice Guidelines:Wilson's disease [J]. J Hepatol,2012,56(3): 671-85.
[3]ROBERTS E A, SCHILSKY M L. Diagnosis and treatment of Wilson disease:an update [J]. Hepatology,2008,47(6):2089-111.
[4]BULL P C, THOMAS G R, ROMMENS J M, et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene [J]. Nat Genet, 1993,5(4):327-37.
[5]KENNEY S M, COX D W. Sequence variation database for the Wilson disease copper transporter, ATP7B [J]. Human mutation,2007,28(12):1171-7.
[6]LEPORI M B, ZAPPU A, INCOLLU S, et al. Mutation analysis of the ATP7B gene in a new group of Wilson's disease patients:Contribution to diagnosis [J]. Mol Cell Probes, 2012,
[7]KUCINSKAS L, JEROCH J, VITKAUSKIENE A, et al. High frequency of the c. 3207C＞ (p. H1069Q) mutation in ATP7B gene of Lithuanian patients with hepatic presentation of Wilson's disease [J]. World journal of gastroenterology:WJG,2008,14(38): 5876.
[8]VRABELOVA S, LETOCHA O, BORSKY M, et al. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease [J]. Molecular genetics and metabolism,2005,86(1):277-85.
[9]LIU X Q, ZHANG Y F, LIU T T, et al. Correlation of ATP7B genotype with phenotype in Chinese patients with Wilson disease [J]. World Journal of Gastroenterology,2004,10(4): 590-3.
[10]LI X H, LU Y, LING Y, et al. Clinical and molecular characterization of Wilson's disease in China:identification of 14 novel mutations [J]. BMC Med Genet,2011,12(6.
[11]LEE B H, KIM J H, LEE S Y, et al. Distinct clinical courses according to presenting phenotypes and their correlations to ATP7B mutations in a large Wilson's disease cohort [J]. Liver International,2011,
[12]PANICHAREON B, TAWEECHUE K, THONGNOPPAKHUN W, et al. Six novel ATP7B mutations in Thai patients with Wilson disease [J]. European Journal of Medical Genetics,2011,54(2):103-7.
[13]HUSTER D, K HNE A, BHATTACHARJEE A, et al. Diverse Functional Properties of Wilson Disease ATP7B Variants [J]. Gastroenterology,2012,
[14]FERENCI P, ROBERTS E A. Defining Wilson Disease Phenotypes:From the Patient to the Bench and Back Again [J]. Gastroenterology,2012,142(4):692-6.
[15]TATSUMI Y, HATTORI A, HAYASHI H, et al. Current state of Wilson disease patients in central Japan [J]. Internal Medicine,2010,49(9):809-15.
[16]MACHADO A A C, DEGUTI M M, GENSCHEL J, et al. Neurological manifestations and ATP7B mutations in Wilson's disease [J]. Parkinsonism & Related Disorders,2008, 14(3):246-9.
[17]EASL clinical practice guidelines for HFE hemochromatosis [J]. J Hepatol,2010, 53(1):3-22.
[18]BACON, ADAMS, KOWDLEY,et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases [J]. Hepatology,2011,54(1):328-43.
[19]FEDER J N, GNIRKE A, THOMAS W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis [J]. Nat Genet,1996,13(4): 399-408.
[20]EIJKELKAMP,YAPP T R,POWELL L W.HFE-associated hereditary hemochromatosis [J]. Can J Gastroenterol,2000,14(2):121-5.
[21]MCLAREN,GARNER C, CONSTANTINE C C, et al. Genome-wide association study identifies genetic Loci associated with iron deficiency [J]. PloS one,2011,6(3):e17390.
[22]Kowdley KV,Tait JF,Bennett RL,Motulsky AG GeneReviews. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1116/?part+=hemochromatosis#hemochromatosis .grID2784. (Revised 2012). [M/OL].
[23]CAMASCHELLA C, ROETTO A, CAL A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22 [J]. Nature genetics,2000,25(1):14-5.
[24]SHAM R L, PHATAK P D, WEST C, et al. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features [J]. Blood Cells, Molecules, and Diseases,2005,34(2):157-61.
[25]LOK C Y, MERRYWEATHER-CLARKE A T, VIPRAKASIT V, et al. Iron overload in the Asian community [J]. Blood,2009,114(1):20-5.
[26]PAPANIKOLAOU G, SAMUELS M E, LUDWIG E H, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis [J]. Nature genetics, 2003,36(1):77-82.
[27]ROETTO A, PAPANIKOLAOU G, POLITOU M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis [J]. Nature genetics,2002, 33(1):21-2.
[28]STOLLER J K, ABOUSSOUAN L S. A review of alpha 1-antitrypsin deficiency [J]. Am J Respir Crit Care Med,2012,185(3):246-59.
[29]RINGENBACH M R, BANTA E, SNYDER M R, et al. A challenging diagnosis of alpha-1-antitrypsin deficiency:identification of a patient with a novel F/Null phenotype [J]. Allergy, asthma, and clinical immunology:official journal of the Canadian Society of Allergy and Clinical Immunology,2011,7(1):18.
[30]RODRIGUEZ-FRIAS F, MIRAVITLLES M, VIDAL R, et al. Rare alpha-1-antitrypsin variants:are they really so rare? [J]. Therapeutic Advances in Respiratory Disease,2012,
[31]STOLLER J, SNIDER G, BRANTLY M, et al. American Thoracic Society/European Respiratory Society Statement:Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency] [J]. Pneumologie (Stuttgart, Germany),2005,59(1): 36.
[32]PIETRANGELO A, OUDE ELFERINK R, PRIETO J, et al. Genetics in liver diseases [J]. Journal of Hepatology,2007,46(6):1143-8.
[33]PIETRANGELO A. Inherited metabolic disease of the liver [J]. Current opinion in gastroenterology,2009,25(3):209.
[34]KRAWCZYK M, M LLENBACH R, WEBER S N, et al. Genome-wide association studies and genetic risk assessment of liver diseases [J]. Nature Reviews Gastroenterology and Hepatology,2010,7(12):669-81.
[35]World Health Organization. Hepatitis B. World Health Organization Fact Sheet No. 204. Available at:http://who.int/mediacentre/factsheets/fs204/en (Revised August 2008). [M].
[36]LOK A S F, MCMAHON B J. Chronic hepatitis B:update 2009 [J]. Hepatology,2009, 50(3):661-2.
[37]EUROPEAN ASSOCIATION FOR THE STUDY OF THE L. EASL Clinical Practice Guidelines:Management of chronic hepatitis B virus infection [J]. J Hepatol,2012,
[38]LIANG X, BI S, YANG W, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination [J]. Vaccine,2009, 27(47):6550-7.
[39]LIANG X, BI S, YANG W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China [J]. Journal of Infectious Diseases,2009, 200(1):39-47.
[40]LU F, ZHUANG H. Management of hepatitis B in China [J]. Chin Med J (Engl),2009, 122(1):3-4.
[41]KAMATANI Y, WATTANAPOKAYAKIT S, OCHI H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians [J]. Nature Genetics,2009,41(5):591-5.
[42]MBAREK H, OCHI H, URABE Y, et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population [J]. Human molecular genetics,2011,20(19):3884-92.
[43]GUO X, ZHANG Y, LI J, et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the han Chinese population [J]. Hepatology,2011,
[44]BERTOLETTI A, WANG L, WU X-P, et al. Evaluation of Genetic Susceptibility Loci for Chronic Hepatitis B in Chinese:Two Independent Case-Control Studies [J]. PLoS ONE, 2011,6(3):e17608.
[45]AN P, WINKLER C, GUAN L, et al. A Common HLA-DPA1 Variant is a Major Determinant of Hepatitis B Virus Clearance in Han Chinese [J]. Journal of Infectious Diseases,2011,203(7):943-7.
[46]LI J, YANG D, HE Y, et al. Associations of HLA-DP Variants with Hepatitis B Virus Infection in Southern and Northern Han Chinese Populations:A Multicenter Case-Control Study [J]. PLoS ONE,2011,6(8):e24221.
[47]HU L, ZHAI X, LIU J, et al. Genetic variants in HLA-DP/DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development [J]. Hepatology,2011,
[48]ZHANG H, ZHAI Y, HU Z, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers [J]. Nature genetics,2010,42(9):755-8.
[49]LAMPERTICO P, VIGAN M, CHERONI C, et al. IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B [J]. Hepatology,2012,
[50]LEI R X, SHI H, PENG X M, et al. Influence of a single nucleotide polymorphism in the P1 promoter of the furin gene on transcription activity and hepatitis B virus infection [J]. Hepatology,2009,50(3):763-71.
[51]DENG G, ZHOU G, ZHANG R, et al. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers [J]. Gastroenterology,2008,134(3):716-26. e2.
[52]World Health Organization. Hepatitis C. World Health Organization Fact Sheet No. 164. Available at:http://www.who.int/mediacentre/factsheets/fs164/en/(Revised June 2011). [M].
[53]KUMAR V, KATO N, URABE Y, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma [J]. Nature genetics,2011, 43(5):455-8.
[54]MIKI D, OCHI H, HAYES C N, et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers [J]. Nature genetics,2011,43(8):797-800.
[55]NALPAS B, LAVIALLE-MEZIANI R, PLANCOULAINE S, et al. Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection [J]. Gut,2010,59(8):1120-6.
[56]GE D, FELLAY J, THOMPSON A J, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance [J]. Nature,2009,461(7262):399-401.
[57]THOMAS D L, THIO C L, MARTIN M P, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus [J]. Nature,2009,461(7265):798-801.
[58]SUPPIAH V, MOLDOVAN M, AHLENSTIEL G, et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy [J]. Nature genetics,2009, 41(10):1100-4.
[59]TANAKA Y, NISHIDA N, SUGIYAMA M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C [J]. Nature genetics,2009,41(10):1105-9.
[60]RAUCH A, KUTALIK Z, DESCOMBES P, et al. Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure:A Genome-Wide Association Study [J]. Gastroenterology,2010,138(4):1338-45. e7.
[61]BOCHUD P Y, BIBERT S, NEGRO F, et al.IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C [J]. Journal of Hepatology, 2011,
[62]BOCHUD P Y, BIBERT S, KUTALIK Z, et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes [J]. Hepatology (Baltimore, Md),2012,55(2):384.
[63]ASSELAH T, DE MUYNCK S, BROET P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C [J]. J Hepatol,2012, 56(3):527-32.
[64]MCGILVRAY I, FELD J J, CHEN L, et al. Hepatic Cell-Type Specific Gene Expression Better Predicts HCV Treatment Outcome Than IL28B Genotype [J]. Gastroenterology,2012,142(5):1122-31 el.
[65]SUPPIAH V, GAUDIERI S, ARMSTRONG N J, et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort:a cross-sectional study [J]. PLoS medicine,2011,8(9):e1001092.
[66]SCHERZER T M, ST TTERMAYER A F, STRASSER M, et al. Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin [J]. Hepatology,2011,54(5):1518-26.
[67]GOLDEN-MASON L, BAMBHA K M, CHENG L, et al. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C [J]. Hepatology,2011,
[68]DILL M T, DUONG F H T, VOGT J E, et al. Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response Than IL28B Genotype in Patients With Hepatitis C [J]. Gastroenterology,2011,140(3):1021-31. e10.
[69]ASAHINA Y, TSUCHIYA K, MURAOKA M, et al. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response [J]. Hepatology,2011,
[70]LANGE C M, KUTALIK Z, MORIKAWA K, et al. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy [J]. Hepatology,2012,55(4):1038-47.
[71]FELLAY J, THOMPSON A J, GE D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C [J]. Nature,2010,464(7287):405-8.
[72]THOMPSON A J, CLARK P J, SINGH A, et al. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients [J]. Journal of Hepatology, 2011,
[73]Understanding Gallstones·AGA. Available at:http://www.gastro.org/(2007). [M/OL].
[74]KATSIKA D, GRJIBOVSKI A, EINARSSON C, et al. Genetic and environmental influences on symptomatic gallstone disease:a Swedish study of 43,141 twin pairs [J]. Hepatology,2005,41(5):1138-43.
[75]LAMMERT F, SAUERBRUCH T. Mechanisms of disease:the genetic epidemiology of gallbladder stones [J]. Nature Reviews Gastroenterology and Hepatology,2005,2(9): 423-33.
[76]GR NHAGE F, ACALOVSCHI M, TIRZIU S, et al. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol [J]. Hepatology,2007,46(3):793-801.
[77]STENDER S, FRIKKE-SCHMIDT R, NORDESTGAARD B G, et al. Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population [J]. Hepatology,2011,53(2): 640-8.
[78]PASMANT E, GOUSSARD P, BARANES L, et al. First description of ABCB4 gene deletions in familial low phospholipid-associated cholelithiasis and oral contraceptives-induced cholestasis [J]. European Journal of Human Genetics,2011,20(3): 277-82.
[79]BUCH S, SCHAFMAYER C, V LZKE H, et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease [J]. Nature genetics,2007,39(8):995-9.
[80]MANNS M P, CZAJA A J, GORHAM J D, et al. Diagnosis and management of autoimmune hepatitis [J]. Hepatology,2010,51(6):2193-213.
[81]CZAJA A J, MANNS M P. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis [J]. Gastroenterology,2010,139(1):58-72. e4.
[82]LIM Y S, OH H B, CHOI S E, et al. Susceptibility to type 1 autoimmune hepatitis is associated with shared amino acid sequences at positions 70-74 of the HLA-DRB1 molecule [J]. Journal of Hepatology,2008,48(1):133-9.
[83]DUARTE-REY C, PARDO A L, RODR GUEZ-VELOSA Y, et al. HLA class II association with autoimmune hepatitis in Latin America:a meta-analysis [J]. Autoimmunity reviews,2009,8(4):325-31.
[84]DJILALI-SAIAH I, FAKHFAKH A, LOUAFI H, et al. HLA class Ⅱ influences humoral autoimmunity in patients with type 2 autoimmune hepatitis [J]. Journal of Hepatology,2006,45(6):844-50.
[85]TANG J, ZHOU C, ZHANG Z J, et al. Association of polymorphisms in non-classic MHC genes with susceptibility to autoimmune hepatitis [J]. Hepatobiliary Pancreat Dis Int, 2012,11(125-31.
[86]OLIVEIRA L C, PORTA G, MARIN M L C, et al. Autoimmune hepatitis, HLA and extended haplotypes [J]. Autoimmunity reviews,2011,10(4):189-93.
[87]YOKOSAWA S, YOSHIZAWA K, OTA M, et al. A genomewide DNA microsatellite association study of Japanese patients with autoimmune hepatitis type 1 [J]. Hepatology, 2007,45(2):384-90.
[88]BOONSTRA K, BEUERS U, PONSIOEN C Y. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:A systematic review [J]. Journal of Hepatology, 2012,
[89]MENDES F, COUTO C A, LEVY C. Recurrent and de novo autoimmune liver diseases [J]. Clinics in liver disease,2011,15(4):859.
[90]LINDOR K D, GERSHWIN M E, POUPON R, et al. Primary biliary cirrhosis [J]. Hepatology,2009,50(1):291-308.
[91]HIRSCHFIELD G M, INVERNIZZI P. Progress in the genetics of primary biliary cirrhosis, F,2011 [C].
[92]UMEMURA T, JOSHITA S, ICHIJO T, et al. Human leukocyte antigen class Ⅱ molecules confer both susceptibility and progression in japanese patients with primary biliary cirrhosis [J]. Hepatology,2012,
[93]HIRSCHFIELD G M, LIU X, XU C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants [J]. New England Journal of Medicine,2009,360(24): 2544-55.
[94]HIRSCHFIELD G M, LIU X, HAN Y, et al. Variants at IRF5-TNPO3,17q12-21 and MMEL1 are associated with primary biliary cirrhosis [J]. Nature genetics,2010,42(8): 655-7.
[95]LIU X, INVERNIZZI P, LU Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis [J]. Nature genetics,2010,42(8):658-60.
[96]MELLS G F, FLOYD J A B, MORLEY K I, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis [J]. Nature genetics,2011, 43(4):329-32.
[97]CHAPMAN R, FEVERY J, KALLOO A, et al. Diagnosis and management of primary sclerosing cholangitis [J]. Hepatology,2010,51(2):660-78.
[98]KARLSEN T H, FRANKE A, MELUM E, et al. Genome-wide association analysis in primary sclerosing cholangitis [J]. Gastroenterology,2010,138(3):1102-11.
[99]MELUM E, FRANKE A, SCHRAMM C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci [J]. Nature genetics,2010,43(1):17-9.
[100]O'SHEA R S, DASARATHY S, MCCULLOUGH A J. Alcoholic liver disease [J]. Hepatology,2010,51(1):307-28.
[101]STICKEL F, HAMPE J. Genetic determinants of alcoholic liver disease [J]. Gut,2012, 61(1):150-9.
[102]TR,GUSTOT,DEGR,et al.Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease [J]. Journal of Hepatology,2011,
[103]STICKEL F, BUCH S, LAU,et al.Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians [J]. Hepatology,2011,53(1):86-95.
[104]ROTMAN,KOH,ZMUDA,et al.The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease [J]. Hepatology,2010,52(3):894-903.
[105]SOOKOIAN S, PIROLA C J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease [J]. Hepatology,2011,53(6): 1883-94.
[106]VALENTI L, AL-SERRI A, DALY A K, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease [J]. Hepatology,2010,51(4):1209-17.
[107]VALENTI L, ALISI A, GALMOZZI E, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease [J]. Hepatology,2010,52(4):1274-80.
[108]SPELIOTES E K, YERGES-ARMSTRONG L M, WU J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits [J]. PLoS genetics,2011,7(3):e1001324.
[109]ROMEO S, KOZLITINA J, XING C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease [J]. Nature genetics,2008,40(12):1461-5.
[110]LI Y, XING C, COHEN J C, et al. Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China [J]. Hepatology,2012,55(1):327-8.
[111]TIAN C, STOKOWSKI R P, KERSHENOBICH D, et al. Variant in PNPLA3 is associated with alcoholic liver disease [J]. Nature genetics,2009,42(1):21-3.
[112]DALY A K, DAY C P. Genetic association studies in drug-induced liver injury, F, 2009 [C].
[113]LUCENA,MOLOKHIA,SHEN,et al.Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class Ⅰ and Ⅱ alleles [J]. Gastroenterology,2011,
[114]SINGER J B, LEWITZKY S, LEROY E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury [J]. Nature genetics,2010,42(8): 711-4.
[115]DALY A K, DONALDSON P T, BHATNAGAR P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin [J]. Nature genetics, 2009,41(7):816-9.
[116]GHANY M G, NELSON D R, STR.ADER D B, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection:2011 practice guideline by the American Association for the Study of Liver Diseases [J]. Hepatology,2011,54(4):1433-44.
[117]CRAX A. EASL Clinical Practice Guidelines:Management of hepatitis C virus infection [J]. Journal of Hepatology,2011,
[118]FEERO W G, GUTTMACHER A E,MANOLIO T A.Genomewide association studies and assessment of the risk of disease [J]. New England Journal of Medicine,2010,363(2): 166-76.
[119]RIENHOFF H Y, JR. Genomewide association studies and assessment of risk of disease [J]. N Engl J Med,2010,363(21):2077; author reply
[120]YANG J J, PLENGE R M. Genomic Technology Applied to Pharmacological Traits [J]. JAMA:The Journal of the American Medical Association,2011,306(6):652.
[121]DALY A K. Genome-wide association studies in pharmacogenomics [J]. Nature Reviews Genetics,2010,11(4):241-6.
[122]ROPERS H H. On the future of genetic risk assessment [J]. Journal of Community Genetics,2012,1-8.
[123]ROYSTON P, MOONS K G M, ALTMAN D,et al.Prognosis and prognostic research: developing a prognostic model [J]. Bmj,2009,338
[124]ALTMAN D G, VERGOUWE Y, ROYSTON,et al.Prognosis and prognostic research: validating a prognostic model [J]. Bmj,2009,338
[125]MARCOLONGO M, YOUNG,DAL PERO,et al.A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C [J]. Hepatology,2009,50(4):1038-44.
[126]KOTRONEN A, PELTONEN M, HAKKARAINEN,et al.Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors [J]. Gastroenterology, 2009,137(3):865-72.
[127]WEI Z, WANG K, QU H Q, et al. From disease association to risk assessment:an optimistic view from genome-wide association studies on type 1 diabetes [J]. PLoS genetics,2009,5(10):e1000678.
[128]PAYNTER N P, CHASMAN D I, PAR, et al.Association between a literature-based genetic risk score and cardiovascular events in women [J]. JAMA:The Journal of the American Medical Association,2010,303(7):631-7.
[129]KATHIRESAN S, MELANDER O, ANEVSKI D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events [J]. New England Journal of Medicine, 2008,358(12):1240-9.
[130]THANASSOULIS G, VASAN R S. Genetic Cardiovascular Risk Prediction Will We Get There? [J]. Circulation,2010,122(22):2323-34.
[131]ROBERTS N J, VOGELSTEIN J T, PARMIGIANI G, et al. The Predictive Capacity of Personal Genome Sequencing [J]. Science Translational Medicine,2012,
[132]MOONS K G M, ALTMAN D G, VERGOUWE Y, et al. Prognosis and prognostic research:application and impact of prognostic models in clinical practice [J]. Bmj,2009, 338
[133]MOONS K G M, ROYSTON P, VERGOUWE Y, et al. Prognosis and prognostic research:what, why, and how? [J]. Bmj,2009,338
[134]KUNG J T,GELBART M E.Getting a Head Start:the importance of Personal Genetics Education in High Schools [J]. The Yale Journal of Biology and Medicine,2012,85(1):87.
[2]World Health Organization. Hepatitis B. World Health Organization Fact Sheet No. 204. Available at:http://who.int/mediacentre/factsheets/fs204/en (Revised August 2008).
[3]KAMATANI Y, WATTANAPOKAYAKIT S, OCHI H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians [J]. Nature genetics,2009,41(5):591-595.
[4]AN P, WINKLER C, GUAN L, et al. A Common HLA-DPA1 Variant is a Major Determinant of Hepatitis B Virus Clearance in Han Chinese [J]. Journal of Infectious Diseases,2011,203(7):943.
[5]GUO X, ZHANG Y, LI J, et al. Strong Influence of HLA-DP Gene Variants on Development of Persistent Chronic HBV Carriers in the Han Chinese Population [J]. Hepatology (Baltimore, Md),2011,53(2):422.
[6]HU L, ZHAI X, LIU J, et al. Genetic variants in HLA-DP/DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development [J]. Hepatology,2011,
[7]LI J, YANG D, HE Y, et al. Associations of HLA-DP Variants with Hepatitis B Virus Infection in Southern and Northern Han Chinese Populations:A Multicenter Case-Control Study [J]. PloS one,2011,6(8):e24221.
[8]MBAREK H, OCHI H, URABE Y, et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population [J]. Human molecular genetics,2011,20(19):3884-3892.
[9]O'BRIEN T, KOHAAR I, PFEIFFER R, et al. Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver [J]. Genes and immunity,2011,12(6):428-433.
[10]PNG E, THALAMUTHU A, ONG R T H, et al. A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region [J]. Human molecular genetics,2011,20(19):3893-3898.
[11]VERMEHREN J, L TSCH J, SUSSER S, et al. A Common HLA-DPA1 Variant Is Associated with Hepatitis B Virus Infection but Fails to Distinguish Active from Inactive Caucasian Carriers [J]. PloS one,2012,7(3):e32605.
[12]WANG L, WU X P, ZHANG W, et al. Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese:two independent case-control studies [J]. PloS one,2011.
[1]World Health Organization. Hepatitis B. World Health Organization Fact Sheet No. 204. Available at:http://who.int/mediacentre/factsheets/fs204/en (Revised August 2008).
[2]LU F, ZHUANG H. Management of hepatitis B in China [J]. Chin Med J (Engl),2009, 122(1):3-4.
[3]EUROPEAN ASSOCIATION FOR THE STUDY OF THE L. EASL Clinical Practice Guidelines:Management of chronic hepatitis B virus infection [J]. J Hepatol,2012.
[4]BAUMERT T F, THIMME R, VON WEIZSACKER F. Pathogenesis of hepatitis B virus infection [J]. World Journal of Gastroenterology,2007,13(1):82.
[5]CHISARI F V, ISOGAWA M, WIELAND S F. Pathogenesis of hepatitis B virus infection [J]. Pathologie Biologie,2010,58(4):258-266.
[6]BERTOLETTI A, FERRARI C. Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection [J]. Gut,2011.
[7]BAUER T, SPRINZL M, PROTZER U. Immune control of hepatitis B virus [J]. Digestive Diseases,2011,29(4):423-433.
[8]DUNN C, PEPPA D, KHANNA P, et al. Temporal Analysis of Early Immune Responses in Patients With Acute Hepatitis B Virus Infection [J]. Gastroenterology,2009, 137(4):1289-1300.
[9]KAMATANI Y, WATTANAPOKAYAKIT S, OCHI H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians [J]. Nature Genetics,2009,41(5):591-595.
[10]ZHANG H, ZHAI Y, HU Z, et al. Genome-wide association study identifies Ip36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers [J]. Nature Genetics,2010,42(9):755-758.
[11]THURSZ M R, KWIATKOWSKI D, ALLSOPP C E, et al. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia [J]. N Engl J Med, 1995,332(16):1065-1069.
[12]JIANG Y G, WANG Y M, LIU T H, et al. Association between HLA class Ⅱ gene and susceptibility or resistance to chronic hepatitis B [J]. World Journal of Gastroenterology, 2003,9(10):2221-2225.
[13]AHN S H, HAN K H, PARK J Y, et al. Association between hepatitis B virus infection and HLA-DR type in Korea [J]. Hepatology,2000,31(6):1371-1373.
[14]卫生部.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6)：324-329.
[15]中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病 与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9)：643-646.
[16]王宇明,张南.从慢加急性肝衰竭(ACLF)共识讨论到肝衰竭定义和分型诊断,F,2009[C].
[17]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病杂志,2011,19(1)：13-24.
[18]WILLIAM M, ANNE M, R.TODD. AASLD position paper:The management of acute liver failure:Update 2011 [J]. Hepatology,2011,8.
[19]DENG G, ZHOU G, ZHANG R, et al. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers [J]. Gastroenterology,2008,134(3):716-726. e712.
[20]DIENSTAG J L. Hepatitis B virus infection [J]. New England Journal of Medicine, 2008,359(14):1486-1500.
[21]GANEM D, PRINCE A M. Hepatitis B virus infection—natural history and clinical consequences [J]. New England Journal of Medicine,2004,350(11):1118-1129.
[22]LOK A S F, MCMAHON B J. Chronic hepatitis B:update 2009 [J]. Hepatology,2009, 50(3):661-662.
[23]SARIN S K, KUMAR A, ALMEIDA J A, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) [J]. Hepatology international,2009,3(1):269-282.
[24]PRIETO J. Inflammation, HCC and sex:IL-6 in the centre of the triangle [J]. Journal of Hepatology,2008,48(2):380-381.
[25]CHEN S, YEH J, CHANG M, et al. Gender Difference of Alanine Aminotransferase Elevation May Be Associated with Higher Hemoglobin Levels among Male Adolescents [J]. PLoS ONE,2010,5(10):e13269.
[26]NAUGLER W, SAKURAI T, KIM S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production [J]. Science,2007,317(5834):121.
[27]WANG S-H, YEH S-H, LIN W-H, et al. Identification of androgen response elements in the enhancer I of hepatitis B virus:A mechanism for sex disparity in chronic hepatitis B [J]. Hepatology,2009,50(5):1392-1402.
[28]TRACHTENBERG E, VINSON M, HAYES E, et al. HLA class Ⅰ (A, B, C) and class Ⅱ (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China [J]. Tissue antigens,2007,70(6):455-463.
[29]YANG G, DENG Y J, HU S N, et al. HLA-A,-B, and -DRB1 polymorphism defined by sequence-based typing of the Han population in Northern China [J]. Tissue antigens, 2006,67(2):146-152.
[30]SINGH R, KAUL R, KAUL A, et al. A comparative review of HLA associations with hepatitis B and C viral infections across global populations [J]. WORLD JOURNAL OF GASTROENTEROLOGY,2007,13(12):1770.
[31]WEN B, LI H, LU D, et al. Genetic evidence supports demic diffusion of Han culture [J]. Nature,2004,431(7006):302-305.
[32]ZHANG F, SU B, ZHANG Y P, et al. Genetic studies of human diversity in East Asia [J]. Philos Trans R Soc Lond B Biol Sci,2007,362(1482):987-995.
[33]ZHAO T M, LEE T D. Gm and Km allotypes in 74 Chinese populations:a hypothesis of the origin of the Chinese nation [J]. Hum Genet,1989,83(2):101-110.
[34]CHAIX R, CAO C, DONNELLY P. Is mate choice in humans MHC-dependent? [J]. PLoS Genet,2008,4(9):e1000184.
[35]BARREIRO L B, QUINTANA-MURCI L. From evolutionary genetics to human immunology:how selection shapes host defence genes [J]. Nat Rev Genet,2010,11(1): 17-30.
[36]PRUGNOLLE F, MANICA A, CHARPENTIER M, et al. Pathogen-driven selection and worldwide HLA class Ⅰ diversity [J]. Curr Biol,2005,15(11):1022-1027.
[37]ZENG G, WANG Z, WEN S, et al. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China [J]. J Viral Hepat,2005,12(6): 609-617.
[38]HUANG Z J, ZHOU M G, WANG L J. Study on the geographic distribution of liver cancer mortality and HBsAg carrier rate in China [J]. Disease Surveillance (Chinese),2007, 22(4):242-245.
[39]GIOVANNA F, BORTOLOTTI F, FRANCESCO D. Natural history of chronic hepatitis B:Special emphasis on disease progression and prognostic factors☆ [J]. Journal of Hepatology,2008,48(2):335-352.
[40]YANG H, LU S, LIAW Y, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma [J]. New England Journal of Medicine,2002,347(3):168.
[41]HANDUNNETTHI L, RAMAGOPALAN S V, EBERS G C, et al. Regulation of major histocompatibility complex class Ⅱ gene expression, genetic variation and disease [J]. Genes and Immunity,2009,11(2):99-112.
[42]LLOVET J M, BURROUGHS A, BRUIX J. Hepatocellular carcinoma [J]. Lancet, 2003,362(9399):1907-1917.
[43]CHEN J D, YANG H I, ILOEJE U H, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death [J]. Gastroenterology,2010, 138(5):1747-1754. e1741.
[44]ZHOU Y H, WU C, ZHUANG H. Vaccination against hepatitis B:the Chinese experience [J]. Chin Med J (Engl),2009,122(1):98-102.
[45]ZHANG H, ZHAI Y, HU Z, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers [J]. Nat Genet,2010,42(9):755-758.
[46]GRIVENNIKOV S I, GRETEN F R, KARIN M. Immunity, Inflammation, and Cancer [J]. Cell,2010,140(6):883-899.
[1]VISSCHER P M, BROWN M A, MCCARTHY M I, et al. Five Years of GWAS Discovery [J]. American journal of human genetics,2012,90(1):7.
[2]GIBSON G. Rare and common variants:twenty arguments [J]. Nature Reviews Genetics,2012,13(2):135-145.
[3]DAVEY, HOHENLOHE, ETTER, et al. Genome-wide genetic marker discovery and genotyping using next-generation sequencing [J]. Nature Reviews Genetics,2011,12(7).
[4]RAYCHAUDHURI S. Mapping rare and common causal alleles for complex human diseases [J]. Cell,2011,147(1):57-69.
[5]PRICE, ZAITLEN, REICH D, et al. New approaches to population stratification in genome-wide association studies [J]. Nature Reviews Genetics,2010,11(7):459-463.
[6]JACOBS K B, YEAGER M, WACHOLDER S, et al. A new statistic and its power to infer membership in a genome-wide association study using genotype frequencies [J]. Nature genetics,2009,41(11):1253-1257.
[7]CANTOR R M, LANGE K, SINSHEIMER J S. Prioritizing GWAS results:A review of statistical methods and recommendations for their application [J]. The American Journal of Human Genetics,2010,86(1):6-22.
[8]DERSIMONIAN R, LAIRD N. Meta-analysis in clinical trials [J]. Controlled clinical trials,1986,7(3):177-188.
[9]HEDGES L V, OLKIN I, STATISTIKER M. Statistical methods for meta-analysis [M]. Academic Press Orlando, FL.1985.
[10]STROUP D F, BERLIN J A, MORTON S C, et al. Meta-analysis of observational studies in epidemiology [J]. JAMA:the journal of the American Medical Association,2000, 283(15):2008-2012.
[11]HIGGINS J, THOMPSON S G Quantifying heterogeneity in a meta-analysis [J]. Statistics in medicine,2002,21(11):1539-1558.
[12]EGGER M, SMITH G D, SCHNEIDER M, et al. Bias in meta-analysis detected by a simple, graphical test [J]. Bmj,1997,315(7109):629-634.
[13]KAMATANI Y, WATTANAPOKAYAKIT S, OCHI H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians [J]. Nature genetics,2009,41(5):591-595.
[14]VERMEHREN J, L TSCH J, SUSSER S, et al. A Common HLA-DPA1 Variant Is Associated with Hepatitis B Virus Infection but Fails to Distinguish Active from Inactive Caucasian Carriers [J]. PloS one,2012,7(3):e32605.
[15]YAN Z, TAN S, DAN Y, et al. Relationship between HLA-DP gene polymorphisms and clearance of chronic hepatitis B virus infections:Case-control study and meta-analysis [J]. Infect Genet Evol,2012,
[16]PNG E, THALAMUTHU A, ONG R T H, et al. A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region [J]. Human molecular genetics,2011,20(19):3893-3898.
[17]THOMAS R, THIO C L, APPS R, et al. A novel variant marking HLA-DP Expression Levels Predicts Hepatitis B Virus Recovery [J]. Journal of Virology,2012,
[18]AN P, WINKLER C, GUAN L, et al. A Common HLA-DPA1 Variant is a Major Determinant of Hepatitis B Virus Clearance in Han Chinese [J]. Journal of Infectious Diseases,2011,203(7):943.
[19]GUO X, ZHANG Y, LI J, et al. Strong Influence of HLA-DP Gene Variants on Development of Persistent Chronic HBV Carriers in the Han Chinese Population [J]. Hepatology (Baltimore, Md),2011,53(2):422.
[20]LI J, YANG D, HE Y, et al. Associations of HLA-DP Variants with Hepatitis B Virus Infection in Southern and Northern Han Chinese Populations:A Multicenter Case-Control Study [J]. PloS one,2011,6(8):e24221.
[21]WANG L, WU X P, ZHANG W, et al. Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese:two independent case-control studies [J]. PloS one,2011, 6(3):e17608.
[22]HU L, ZHAI X, LIU J, et al. Genetic variants in HLA-DP/DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development [J]. Hepatology,2011,
[23]MBAREK H, OCHI H, URABE Y, et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population [J]. Human molecular genetics,2011,20(19):3884-3892.
[24]O'BRIEN T, KOHAAR I, PFEIFFER R, et al. Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver [J]. Genes and immunity,2011,12(6):428-433.
[25]RAYCHAUDHURI S, SANDOR C, STAHL E A, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis [J]. Nature genetics,2012,44(3):291-296.
[26]COZEN W, LI D, BEST T, et al. A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32 [J]. Blood,2012,119(2):469-475.
[27]VIGNAL C M, BANS AL A T, BALDING D J. Using Penalised Logistic Regression to Fine Map HLA Variants for Rheumatoid Arthritis [J]. Annals of Human Genetics,2011,
[28]NOGUCHI E, SAKAMOTO H, HIROTA T, et al. Genome-wide association study identifies HLA-DP as a susceptibility gene for pediatric asthma in asian populations [J]. PLoS genetics,2011,7(7):e1002170.
[29]IVANSSON E, JUKO-PECIREP I, ERLICH H, et al. Pathway-based analysis of genetic susceptibility to cervical cancer in situ:HLA-DPB1 affects risk in Swedish women [J]. Genes and immunity,2011,
[30]ZHOU X, LEE J E, ARNETT F C, et al. HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis:A genome-wide association study in Koreans with replication in North Americans [J]. Arthritis & Rheumatism,2009,60(12):3807-3814.
[31]MOONS AMY P, BONELLA P, GOODWIN G, et al. The identification of a new HLA-DPB1 allele (* 1302) in one family and the detection of a recombination event between the DR and the DQ regions in another Caucasian T1DGC family [J]. Tissue antigens,2009,74(3):268-270.
[32]SELVARAJ P, RAGHAVAN S, SWAMINATHAN S, et al. HLA-DQB1 and -DPB1 allele profile in HIV infected patients with and without pulmonary tuberculosis of south India [J]. Infect Genet Evol,2008,8(5):664-671.
[33]HOLLENBACH J A, MADBOULY A, GRAGERT L, et al. A combined DPA1 approximately DPB1 amino acid epitope is the primary unit of selection on the HLA-DP heterodimer [J]. Immunogenetics,2012,
[34]ANDREATTA M, NIELSEN M. Characterizing the binding motifs of 11 common human HLA-DP and HLA-DQ molecules using NNAlign [J]. Immunology,2012,
[35]LAUTERBACH N, VOORTER C, STALLINGA C, et al. Full-length HLA-DPB1 diversity in multiple alleles of individuals from Caucasian, Black, or Oriental origin [J]. Tissue antigens,2012,
[36]LV N, DANG A, WANG Z, et al. Association of susceptibility to Takayasu arteritis in Chinese Han patients with HLA-DPB1 [J]. Human Immunology,2011,
[37]TRAVIS R C, REEVES G K, GREEN J, et al. Gene-environment interactions in 7610 women with breast cancer:prospective evidence from the Million Women Study [J]. The Lancet,2010,375(9732):2143-2151.
[1]FDA. Pharmacogenomic Biomarkers in Drug. Available at:http://www.fda.gov/Drugs /ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378htm(Updated 04/26/2012).
[2]EASL Clinical Practice Guidelines:Wilson's disease [J]. J Hepatol,2012,56(3): 671-85.
[3]ROBERTS E A, SCHILSKY M L. Diagnosis and treatment of Wilson disease:an update [J]. Hepatology,2008,47(6):2089-111.
[4]BULL P C, THOMAS G R, ROMMENS J M, et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene [J]. Nat Genet, 1993,5(4):327-37.
[5]KENNEY S M, COX D W. Sequence variation database for the Wilson disease copper transporter, ATP7B [J]. Human mutation,2007,28(12):1171-7.
[6]LEPORI M B, ZAPPU A, INCOLLU S, et al. Mutation analysis of the ATP7B gene in a new group of Wilson's disease patients:Contribution to diagnosis [J]. Mol Cell Probes, 2012,
[7]KUCINSKAS L, JEROCH J, VITKAUSKIENE A, et al. High frequency of the c. 3207C＞ (p. H1069Q) mutation in ATP7B gene of Lithuanian patients with hepatic presentation of Wilson's disease [J]. World journal of gastroenterology:WJG,2008,14(38): 5876.
[8]VRABELOVA S, LETOCHA O, BORSKY M, et al. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease [J]. Molecular genetics and metabolism,2005,86(1):277-85.
[9]LIU X Q, ZHANG Y F, LIU T T, et al. Correlation of ATP7B genotype with phenotype in Chinese patients with Wilson disease [J]. World Journal of Gastroenterology,2004,10(4): 590-3.
[10]LI X H, LU Y, LING Y, et al. Clinical and molecular characterization of Wilson's disease in China:identification of 14 novel mutations [J]. BMC Med Genet,2011,12(6.
[11]LEE B H, KIM J H, LEE S Y, et al. Distinct clinical courses according to presenting phenotypes and their correlations to ATP7B mutations in a large Wilson's disease cohort [J]. Liver International,2011,
[12]PANICHAREON B, TAWEECHUE K, THONGNOPPAKHUN W, et al. Six novel ATP7B mutations in Thai patients with Wilson disease [J]. European Journal of Medical Genetics,2011,54(2):103-7.
[13]HUSTER D, K HNE A, BHATTACHARJEE A, et al. Diverse Functional Properties of Wilson Disease ATP7B Variants [J]. Gastroenterology,2012,
[14]FERENCI P, ROBERTS E A. Defining Wilson Disease Phenotypes:From the Patient to the Bench and Back Again [J]. Gastroenterology,2012,142(4):692-6.
[15]TATSUMI Y, HATTORI A, HAYASHI H, et al. Current state of Wilson disease patients in central Japan [J]. Internal Medicine,2010,49(9):809-15.
[16]MACHADO A A C, DEGUTI M M, GENSCHEL J, et al. Neurological manifestations and ATP7B mutations in Wilson's disease [J]. Parkinsonism & Related Disorders,2008, 14(3):246-9.
[17]EASL clinical practice guidelines for HFE hemochromatosis [J]. J Hepatol,2010, 53(1):3-22.
[18]BACON, ADAMS, KOWDLEY,et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases [J]. Hepatology,2011,54(1):328-43.
[19]FEDER J N, GNIRKE A, THOMAS W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis [J]. Nat Genet,1996,13(4): 399-408.
[20]EIJKELKAMP,YAPP T R,POWELL L W.HFE-associated hereditary hemochromatosis [J]. Can J Gastroenterol,2000,14(2):121-5.
[21]MCLAREN,GARNER C, CONSTANTINE C C, et al. Genome-wide association study identifies genetic Loci associated with iron deficiency [J]. PloS one,2011,6(3):e17390.
[22]Kowdley KV,Tait JF,Bennett RL,Motulsky AG GeneReviews. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1116/?part+=hemochromatosis#hemochromatosis .grID2784. (Revised 2012). [M/OL].
[23]CAMASCHELLA C, ROETTO A, CAL A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22 [J]. Nature genetics,2000,25(1):14-5.
[24]SHAM R L, PHATAK P D, WEST C, et al. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features [J]. Blood Cells, Molecules, and Diseases,2005,34(2):157-61.
[25]LOK C Y, MERRYWEATHER-CLARKE A T, VIPRAKASIT V, et al. Iron overload in the Asian community [J]. Blood,2009,114(1):20-5.
[26]PAPANIKOLAOU G, SAMUELS M E, LUDWIG E H, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis [J]. Nature genetics, 2003,36(1):77-82.
[27]ROETTO A, PAPANIKOLAOU G, POLITOU M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis [J]. Nature genetics,2002, 33(1):21-2.
[28]STOLLER J K, ABOUSSOUAN L S. A review of alpha 1-antitrypsin deficiency [J]. Am J Respir Crit Care Med,2012,185(3):246-59.
[29]RINGENBACH M R, BANTA E, SNYDER M R, et al. A challenging diagnosis of alpha-1-antitrypsin deficiency:identification of a patient with a novel F/Null phenotype [J]. Allergy, asthma, and clinical immunology:official journal of the Canadian Society of Allergy and Clinical Immunology,2011,7(1):18.
[30]RODRIGUEZ-FRIAS F, MIRAVITLLES M, VIDAL R, et al. Rare alpha-1-antitrypsin variants:are they really so rare? [J]. Therapeutic Advances in Respiratory Disease,2012,
[31]STOLLER J, SNIDER G, BRANTLY M, et al. American Thoracic Society/European Respiratory Society Statement:Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency] [J]. Pneumologie (Stuttgart, Germany),2005,59(1): 36.
[32]PIETRANGELO A, OUDE ELFERINK R, PRIETO J, et al. Genetics in liver diseases [J]. Journal of Hepatology,2007,46(6):1143-8.
[33]PIETRANGELO A. Inherited metabolic disease of the liver [J]. Current opinion in gastroenterology,2009,25(3):209.
[34]KRAWCZYK M, M LLENBACH R, WEBER S N, et al. Genome-wide association studies and genetic risk assessment of liver diseases [J]. Nature Reviews Gastroenterology and Hepatology,2010,7(12):669-81.
[35]World Health Organization. Hepatitis B. World Health Organization Fact Sheet No. 204. Available at:http://who.int/mediacentre/factsheets/fs204/en (Revised August 2008). [M].
[36]LOK A S F, MCMAHON B J. Chronic hepatitis B:update 2009 [J]. Hepatology,2009, 50(3):661-2.
[37]EUROPEAN ASSOCIATION FOR THE STUDY OF THE L. EASL Clinical Practice Guidelines:Management of chronic hepatitis B virus infection [J]. J Hepatol,2012,
[38]LIANG X, BI S, YANG W, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination [J]. Vaccine,2009, 27(47):6550-7.
[39]LIANG X, BI S, YANG W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China [J]. Journal of Infectious Diseases,2009, 200(1):39-47.
[40]LU F, ZHUANG H. Management of hepatitis B in China [J]. Chin Med J (Engl),2009, 122(1):3-4.
[41]KAMATANI Y, WATTANAPOKAYAKIT S, OCHI H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians [J]. Nature Genetics,2009,41(5):591-5.
[42]MBAREK H, OCHI H, URABE Y, et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population [J]. Human molecular genetics,2011,20(19):3884-92.
[43]GUO X, ZHANG Y, LI J, et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the han Chinese population [J]. Hepatology,2011,
[44]BERTOLETTI A, WANG L, WU X-P, et al. Evaluation of Genetic Susceptibility Loci for Chronic Hepatitis B in Chinese:Two Independent Case-Control Studies [J]. PLoS ONE, 2011,6(3):e17608.
[45]AN P, WINKLER C, GUAN L, et al. A Common HLA-DPA1 Variant is a Major Determinant of Hepatitis B Virus Clearance in Han Chinese [J]. Journal of Infectious Diseases,2011,203(7):943-7.
[46]LI J, YANG D, HE Y, et al. Associations of HLA-DP Variants with Hepatitis B Virus Infection in Southern and Northern Han Chinese Populations:A Multicenter Case-Control Study [J]. PLoS ONE,2011,6(8):e24221.
[47]HU L, ZHAI X, LIU J, et al. Genetic variants in HLA-DP/DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development [J]. Hepatology,2011,
[48]ZHANG H, ZHAI Y, HU Z, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers [J]. Nature genetics,2010,42(9):755-8.
[49]LAMPERTICO P, VIGAN M, CHERONI C, et al. IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B [J]. Hepatology,2012,
[50]LEI R X, SHI H, PENG X M, et al. Influence of a single nucleotide polymorphism in the P1 promoter of the furin gene on transcription activity and hepatitis B virus infection [J]. Hepatology,2009,50(3):763-71.
[51]DENG G, ZHOU G, ZHANG R, et al. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers [J]. Gastroenterology,2008,134(3):716-26. e2.
[52]World Health Organization. Hepatitis C. World Health Organization Fact Sheet No. 164. Available at:http://www.who.int/mediacentre/factsheets/fs164/en/(Revised June 2011). [M].
[53]KUMAR V, KATO N, URABE Y, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma [J]. Nature genetics,2011, 43(5):455-8.
[54]MIKI D, OCHI H, HAYES C N, et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers [J]. Nature genetics,2011,43(8):797-800.
[55]NALPAS B, LAVIALLE-MEZIANI R, PLANCOULAINE S, et al. Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection [J]. Gut,2010,59(8):1120-6.
[56]GE D, FELLAY J, THOMPSON A J, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance [J]. Nature,2009,461(7262):399-401.
[57]THOMAS D L, THIO C L, MARTIN M P, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus [J]. Nature,2009,461(7265):798-801.
[58]SUPPIAH V, MOLDOVAN M, AHLENSTIEL G, et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy [J]. Nature genetics,2009, 41(10):1100-4.
[59]TANAKA Y, NISHIDA N, SUGIYAMA M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C [J]. Nature genetics,2009,41(10):1105-9.
[60]RAUCH A, KUTALIK Z, DESCOMBES P, et al. Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure:A Genome-Wide Association Study [J]. Gastroenterology,2010,138(4):1338-45. e7.
[61]BOCHUD P Y, BIBERT S, NEGRO F, et al.IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C [J]. Journal of Hepatology, 2011,
[62]BOCHUD P Y, BIBERT S, KUTALIK Z, et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes [J]. Hepatology (Baltimore, Md),2012,55(2):384.
[63]ASSELAH T, DE MUYNCK S, BROET P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C [J]. J Hepatol,2012, 56(3):527-32.
[64]MCGILVRAY I, FELD J J, CHEN L, et al. Hepatic Cell-Type Specific Gene Expression Better Predicts HCV Treatment Outcome Than IL28B Genotype [J]. Gastroenterology,2012,142(5):1122-31 el.
[65]SUPPIAH V, GAUDIERI S, ARMSTRONG N J, et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort:a cross-sectional study [J]. PLoS medicine,2011,8(9):e1001092.
[66]SCHERZER T M, ST TTERMAYER A F, STRASSER M, et al. Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin [J]. Hepatology,2011,54(5):1518-26.
[67]GOLDEN-MASON L, BAMBHA K M, CHENG L, et al. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C [J]. Hepatology,2011,
[68]DILL M T, DUONG F H T, VOGT J E, et al. Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response Than IL28B Genotype in Patients With Hepatitis C [J]. Gastroenterology,2011,140(3):1021-31. e10.
[69]ASAHINA Y, TSUCHIYA K, MURAOKA M, et al. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response [J]. Hepatology,2011,
[70]LANGE C M, KUTALIK Z, MORIKAWA K, et al. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy [J]. Hepatology,2012,55(4):1038-47.
[71]FELLAY J, THOMPSON A J, GE D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C [J]. Nature,2010,464(7287):405-8.
[72]THOMPSON A J, CLARK P J, SINGH A, et al. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients [J]. Journal of Hepatology, 2011,
[73]Understanding Gallstones·AGA. Available at:http://www.gastro.org/(2007). [M/OL].
[74]KATSIKA D, GRJIBOVSKI A, EINARSSON C, et al. Genetic and environmental influences on symptomatic gallstone disease:a Swedish study of 43,141 twin pairs [J]. Hepatology,2005,41(5):1138-43.
[75]LAMMERT F, SAUERBRUCH T. Mechanisms of disease:the genetic epidemiology of gallbladder stones [J]. Nature Reviews Gastroenterology and Hepatology,2005,2(9): 423-33.
[76]GR NHAGE F, ACALOVSCHI M, TIRZIU S, et al. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol [J]. Hepatology,2007,46(3):793-801.
[77]STENDER S, FRIKKE-SCHMIDT R, NORDESTGAARD B G, et al. Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population [J]. Hepatology,2011,53(2): 640-8.
[78]PASMANT E, GOUSSARD P, BARANES L, et al. First description of ABCB4 gene deletions in familial low phospholipid-associated cholelithiasis and oral contraceptives-induced cholestasis [J]. European Journal of Human Genetics,2011,20(3): 277-82.
[79]BUCH S, SCHAFMAYER C, V LZKE H, et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease [J]. Nature genetics,2007,39(8):995-9.
[80]MANNS M P, CZAJA A J, GORHAM J D, et al. Diagnosis and management of autoimmune hepatitis [J]. Hepatology,2010,51(6):2193-213.
[81]CZAJA A J, MANNS M P. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis [J]. Gastroenterology,2010,139(1):58-72. e4.
[82]LIM Y S, OH H B, CHOI S E, et al. Susceptibility to type 1 autoimmune hepatitis is associated with shared amino acid sequences at positions 70-74 of the HLA-DRB1 molecule [J]. Journal of Hepatology,2008,48(1):133-9.
[83]DUARTE-REY C, PARDO A L, RODR GUEZ-VELOSA Y, et al. HLA class II association with autoimmune hepatitis in Latin America:a meta-analysis [J]. Autoimmunity reviews,2009,8(4):325-31.
[84]DJILALI-SAIAH I, FAKHFAKH A, LOUAFI H, et al. HLA class Ⅱ influences humoral autoimmunity in patients with type 2 autoimmune hepatitis [J]. Journal of Hepatology,2006,45(6):844-50.
[85]TANG J, ZHOU C, ZHANG Z J, et al. Association of polymorphisms in non-classic MHC genes with susceptibility to autoimmune hepatitis [J]. Hepatobiliary Pancreat Dis Int, 2012,11(125-31.
[86]OLIVEIRA L C, PORTA G, MARIN M L C, et al. Autoimmune hepatitis, HLA and extended haplotypes [J]. Autoimmunity reviews,2011,10(4):189-93.
[87]YOKOSAWA S, YOSHIZAWA K, OTA M, et al. A genomewide DNA microsatellite association study of Japanese patients with autoimmune hepatitis type 1 [J]. Hepatology, 2007,45(2):384-90.
[88]BOONSTRA K, BEUERS U, PONSIOEN C Y. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:A systematic review [J]. Journal of Hepatology, 2012,
[89]MENDES F, COUTO C A, LEVY C. Recurrent and de novo autoimmune liver diseases [J]. Clinics in liver disease,2011,15(4):859.
[90]LINDOR K D, GERSHWIN M E, POUPON R, et al. Primary biliary cirrhosis [J]. Hepatology,2009,50(1):291-308.
[91]HIRSCHFIELD G M, INVERNIZZI P. Progress in the genetics of primary biliary cirrhosis, F,2011 [C].
[92]UMEMURA T, JOSHITA S, ICHIJO T, et al. Human leukocyte antigen class Ⅱ molecules confer both susceptibility and progression in japanese patients with primary biliary cirrhosis [J]. Hepatology,2012,
[93]HIRSCHFIELD G M, LIU X, XU C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants [J]. New England Journal of Medicine,2009,360(24): 2544-55.
[94]HIRSCHFIELD G M, LIU X, HAN Y, et al. Variants at IRF5-TNPO3,17q12-21 and MMEL1 are associated with primary biliary cirrhosis [J]. Nature genetics,2010,42(8): 655-7.
[95]LIU X, INVERNIZZI P, LU Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis [J]. Nature genetics,2010,42(8):658-60.
[96]MELLS G F, FLOYD J A B, MORLEY K I, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis [J]. Nature genetics,2011, 43(4):329-32.
[97]CHAPMAN R, FEVERY J, KALLOO A, et al. Diagnosis and management of primary sclerosing cholangitis [J]. Hepatology,2010,51(2):660-78.
[98]KARLSEN T H, FRANKE A, MELUM E, et al. Genome-wide association analysis in primary sclerosing cholangitis [J]. Gastroenterology,2010,138(3):1102-11.
[99]MELUM E, FRANKE A, SCHRAMM C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci [J]. Nature genetics,2010,43(1):17-9.
[100]O'SHEA R S, DASARATHY S, MCCULLOUGH A J. Alcoholic liver disease [J]. Hepatology,2010,51(1):307-28.
[101]STICKEL F, HAMPE J. Genetic determinants of alcoholic liver disease [J]. Gut,2012, 61(1):150-9.
[102]TR,GUSTOT,DEGR,et al.Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease [J]. Journal of Hepatology,2011,
[103]STICKEL F, BUCH S, LAU,et al.Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians [J]. Hepatology,2011,53(1):86-95.
[104]ROTMAN,KOH,ZMUDA,et al.The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease [J]. Hepatology,2010,52(3):894-903.
[105]SOOKOIAN S, PIROLA C J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease [J]. Hepatology,2011,53(6): 1883-94.
[106]VALENTI L, AL-SERRI A, DALY A K, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease [J]. Hepatology,2010,51(4):1209-17.
[107]VALENTI L, ALISI A, GALMOZZI E, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease [J]. Hepatology,2010,52(4):1274-80.
[108]SPELIOTES E K, YERGES-ARMSTRONG L M, WU J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits [J]. PLoS genetics,2011,7(3):e1001324.
[109]ROMEO S, KOZLITINA J, XING C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease [J]. Nature genetics,2008,40(12):1461-5.
[110]LI Y, XING C, COHEN J C, et al. Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China [J]. Hepatology,2012,55(1):327-8.
[111]TIAN C, STOKOWSKI R P, KERSHENOBICH D, et al. Variant in PNPLA3 is associated with alcoholic liver disease [J]. Nature genetics,2009,42(1):21-3.
[112]DALY A K, DAY C P. Genetic association studies in drug-induced liver injury, F, 2009 [C].
[113]LUCENA,MOLOKHIA,SHEN,et al.Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class Ⅰ and Ⅱ alleles [J]. Gastroenterology,2011,
[114]SINGER J B, LEWITZKY S, LEROY E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury [J]. Nature genetics,2010,42(8): 711-4.
[115]DALY A K, DONALDSON P T, BHATNAGAR P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin [J]. Nature genetics, 2009,41(7):816-9.
[116]GHANY M G, NELSON D R, STR.ADER D B, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection:2011 practice guideline by the American Association for the Study of Liver Diseases [J]. Hepatology,2011,54(4):1433-44.
[117]CRAX A. EASL Clinical Practice Guidelines:Management of hepatitis C virus infection [J]. Journal of Hepatology,2011,
[118]FEERO W G, GUTTMACHER A E,MANOLIO T A.Genomewide association studies and assessment of the risk of disease [J]. New England Journal of Medicine,2010,363(2): 166-76.
[119]RIENHOFF H Y, JR. Genomewide association studies and assessment of risk of disease [J]. N Engl J Med,2010,363(21):2077; author reply
[120]YANG J J, PLENGE R M. Genomic Technology Applied to Pharmacological Traits [J]. JAMA:The Journal of the American Medical Association,2011,306(6):652.
[121]DALY A K. Genome-wide association studies in pharmacogenomics [J]. Nature Reviews Genetics,2010,11(4):241-6.
[122]ROPERS H H. On the future of genetic risk assessment [J]. Journal of Community Genetics,2012,1-8.
[123]ROYSTON P, MOONS K G M, ALTMAN D,et al.Prognosis and prognostic research: developing a prognostic model [J]. Bmj,2009,338
[124]ALTMAN D G, VERGOUWE Y, ROYSTON,et al.Prognosis and prognostic research: validating a prognostic model [J]. Bmj,2009,338
[125]MARCOLONGO M, YOUNG,DAL PERO,et al.A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C [J]. Hepatology,2009,50(4):1038-44.
[126]KOTRONEN A, PELTONEN M, HAKKARAINEN,et al.Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors [J]. Gastroenterology, 2009,137(3):865-72.
[127]WEI Z, WANG K, QU H Q, et al. From disease association to risk assessment:an optimistic view from genome-wide association studies on type 1 diabetes [J]. PLoS genetics,2009,5(10):e1000678.
[128]PAYNTER N P, CHASMAN D I, PAR, et al.Association between a literature-based genetic risk score and cardiovascular events in women [J]. JAMA:The Journal of the American Medical Association,2010,303(7):631-7.
[129]KATHIRESAN S, MELANDER O, ANEVSKI D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events [J]. New England Journal of Medicine, 2008,358(12):1240-9.
[130]THANASSOULIS G, VASAN R S. Genetic Cardiovascular Risk Prediction Will We Get There? [J]. Circulation,2010,122(22):2323-34.
[131]ROBERTS N J, VOGELSTEIN J T, PARMIGIANI G, et al. The Predictive Capacity of Personal Genome Sequencing [J]. Science Translational Medicine,2012,
[132]MOONS K G M, ALTMAN D G, VERGOUWE Y, et al. Prognosis and prognostic research:application and impact of prognostic models in clinical practice [J]. Bmj,2009, 338
[133]MOONS K G M, ROYSTON P, VERGOUWE Y, et al. Prognosis and prognostic research:what, why, and how? [J]. Bmj,2009,338
[134]KUNG J T,GELBART M E.Getting a Head Start:the importance of Personal Genetics Education in High Schools [J]. The Yale Journal of Biology and Medicine,2012,85(1):87.